CGON
CG OncologyCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful clinical readouts or a strategic partnership could rapidly re-rate the stock toward premium growth multiples; market attention would likely amplify upside given limited public float and concentrated event risk [#SERP-1].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.8.
What can break
Clinical readout failure or delay
Momentum
45
Value
41
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $63.80 · Bull $88.77 · Bear $38.84
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $80.43
Why
Momentum45 · Δ7d -27.9
Value41 · Δ7d +0.1
Sentiment64 · Δ7d +11.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
45
34% active weight
Current posture
7d trendSoftening
Δ7d
-27.9
Δ21d
-36.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
64
33% active weight
Current posture
7d trendImproving
Δ7d
+11.8
Δ21d
+23.7
Why this grade
Composite grade C. Momentum 45.0 / Value 41.1 / Sentiment 64.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$5.22B
Beta
-
Shares Out
80.67M
P/E (TTM) · Derived
-31.1
P/S (TTM)
1485.68
P/FCF (TTM) · Derived
-41.22
Rev YoY
+3774.4%
EPS YoY
-87.9%
Gross Margin
+4.1%
Op Margin
-8285.3%
Net Debt
-$742M
Current Ratio
22.79
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology